IRS2
IRS2 (Insulin receptor substrate 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Prostate cancer.
Overview
Signalling adapter protein that participates in the signal transduction from two prominent receptor tyrosine kinases, insulin receptor/INSR and insulin-like growth factor I receptor/IGF1R. Plays therefore an important role in development, growth, glucose homeostasis as well as lipid metabolism. Upon phosphorylation by the insulin receptor, functions as a signalling scaffold that propagates insulin action through binding to SH2 domain-containing proteins including the p85 regulatory subunit of PI3K, NCK1, NCK2, GRB2 or SHP2.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Capivasertib and Dual IGF-1R/InsR Inhibitor BMS-754807. Open Targets scores its association with cancer at 0.56 (direct and indirect evidence; datatypes literature 0.93, affected pathway 0.54, animal model 0.78, genetic association 0.58).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · IRS2 (Insulin receptor substrate 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Prostate cancer.
- 1 · What it is
IRS2 (Insulin receptor substrate 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Prostate cancer.
- 2 · What goes wrong in cancer
Signalling adapter protein that participates in the signal transduction from two prominent receptor tyrosine kinases, insulin receptor/INSR and insulin-like growth factor I receptor/IGF1R.
- 3 · How drugs use it
No product in this corpus aims at IRS2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:6126 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9Y4H2 (protein name, function text, keywords and locations (REST API)); CIViC gene IRS2 (2 evidence items, 0 assertions, 1 variants; diseases: Colorectal Cancer, Prostate Cancer (GraphQL API, CC0)); Open Targets ENSG00000185950 (association with cancer (MONDO_0004992) 0.56; (GraphQL API, CC0))
Biology
Signalling adapter protein that participates in the signal transduction from two prominent receptor tyrosine kinases, insulin receptor/INSR and insulin-like growth factor I receptor/IGF1R. Plays therefore an important role in development, growth, glucose homeostasis as well as lipid metabolism. Upon phosphorylation by the insulin receptor, functions as a signalling scaffold that propagates insulin action through binding to SH2 domain-containing proteins including the p85 regulatory subunit of PI3K, NCK1, NCK2, GRB2 or SHP2. Recruitment of GRB2 leads to the activation of the guanine nucleotide exchange factor SOS1 which in turn triggers the Ras/Raf/MEK/MAPK signalling cascade. Activation of the PI3K/AKT pathway is responsible for most of insulin metabolic effects in the cell, and the Ras/Raf/MEK/MAPK is involved in the regulation of gene expression and in cooperation with the PI3K pathway regulates cell growth and differentiation. Acts a positive regulator of the Wnt/beta-catenin signalling pathway through suppression of DVL2 autophagy-mediated degradation leading to cell proliferation. Location: Cytoplasm, cytosol (UniProt). Locus 13q34 (HGNC).
- Colorectal cancer: CIViC evidence names this disease
- Prostate cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"IRS2" OR ABSTRACT:"IRS2" OR TITLE:"insulin receptor substrate 2" OR ABSTRACT:"insulin receptor substrate 2" OR TITLE:"Insulin receptor substrate 2" OR ABSTRACT:"Insulin receptor substrate 2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IRS2, not a curated reading list.